Malignant Transformation in Porokeratosis Ptychotropica: A Systematic Review.

Holger Sudhoff, Chee H Loh, Chris L Tan, Kong B Tan, Peter Goon

Journal: Acta dermato-venereologica 2024;104():adv40558

PMID: 39387668

Abstract

Porokeratosis ptychotropica (PP) is a rare and unusual variant of porokeratosis. There is a dearth of information on the natural history, epidemiology, and optimal treatment options. This study aimed to characterize the worldwide distribution, epidemiology, clinical features, and treatments attempted for all reported cases of porokeratosis ptychotropica. A total of 59 cases of porokeratosis ptychotropica have been reported, with most cases originating from the United States. The median age of patients affected with porokeratosis ptychotropica was 49 years. The most involved body locations are the buttocks and gluteal cleft. The risk of malignant transformation in porokeratosis ptychotropica is approximately 1.7% but there is significant bias in estimating rare occurrences in rare diseases. In conclusion, PP is an important but under-recognized variant of porokeratosis, with a likely low risk of malignant transformation. The best available treatment modality remains uncertain; however, the use of topical lovastatin/cholesterol cream appears promising. Long-term surveillance appears prudent for porokeratosis ptychotropica due to a risk of cancerization.

Address: Department of Dermatology, National University Hospital, Singapore. [email protected].; Department of Dermatology, National University Hospital, Singapore.; Department of Pathology, National University Hospital, Singapore.; Department of Otolaryngology, University of Bielefeld, Germany.; Department of Dermatology, National University Hospital, Singapore; Department of Medicine, National University of Singapore, Singapore.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.